Paris, December 19th 2023
Banook Group, the cardiac safety assessment specialist for drug candidates, reinforces its international dimension by welcoming Dr. Mathieu Simon, pharmaceutical and biotechnology industry expert, as independent member to its Supervisory Board.
Founded in 1999 in Nancy, Banook specializes in the centralization of cardiac data derived from electrocardiograms (ECG) and medical imaging to evaluate the safety and efficacy of drug candidates.
For over 25 years, Banook has been supporting pharmaceutical laboratories, biotechnology companies, and Contract Research Organizations (CROs) in conducting their clinical trials, placing scientific and medical expertise at the core of its services.
The Group’s first-class scientific approach is supported by a scientific board spanning a network of renowned Key Opinion Leaders (“KOL”) led by Pr. Etienne Aliot. These experts assist Banook’s clients throughout their clinical trials providing guidance on study calibration (a.o. duration, number of patients, doses, protocols, etc.), regulatory advice, and ECG analysis.
Alongside the Group’s capitalistic evolution, announced on October 19th, 2023, which saw Motion Equity Partners’ entry as majority shareholder, Banook Group is pleased to welcome a pharmaceutical industry expert, Dr. Mathieu Simon, to its Supervisory Board.
Dr. Mathieu Simon brings over 25 years of international experience in executive positions within global pharmaceutical and biotechnology companies. He will continue to support the Group in its next phase of growth, with a strong focus on international development.
After graduating from the Faculté de Médecine de Paris in 1983, Dr. Mathieu Simon spent 20 years at Wyeth Pharmaceuticals as Chairman of multiple subsidiaries as well as in various corporate roles (a.o. Senior VP Head of Global Marketing & Medical Affairs). He later joined the Pierre Fabre Group as Head of Pierre Fabre Pharma and is currently Chairman of the Board of Idorsia (SIX Swiss Exchange) and of the Italian company Aileens Pharma in Milan. He is also Independent Director of Affimed (NASDAQ) and Senior Advisor to Pureos Bioventures in Zurich.
“The appointment of Mathieu Simon as an independent board member aligns with the project of structuring our development. We are delighted to leverage his extensive experience as head of top-tier pharmaceutical groups, along with his strategic and international vision of our markets,” stated Alexandre Durand Salmon, Banook Group CEO.
“Banook is a high potential company which has developed a valuable niche expertise. The company has great development potential, with a client portfolio that proves the quality of its services and operational excellence. It is an honor for me to support the ambitious and exciting project led by Alexandre Durand-Salmon and his team,” stated Mathieu Simon.
Thank you and welcome on board Mathieu Simon !